|Bid||28.87 x 4000|
|Ask||28.87 x 4000|
|Day's Range||28.30 - 29.40|
|52 Week Range||28.30 - 54.93|
|Beta (5Y Monthly)||0.58|
|PE Ratio (TTM)||15.80|
|Earnings Date||Jan 29, 2024 - Feb 02, 2024|
|Forward Dividend & Yield||1.64 (5.67%)|
|Ex-Dividend Date||Nov 09, 2023|
|1y Target Est||40.10|
Subscribe to Yahoo Finance Plus to view Fair Value for PFE
Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine Comirnaty and the treatment Paxlovid -- saw its shares drop about 40%. This includes Pfizer's newer programs and what they may deliver in the future, as well as the company's valuation today. Is Pfizer a buy right now -- or a stock to avoid?
One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). Here are two other issues driving me toward hitting the "sell" button on this pharma stock. Since Albert Bourla took over as CEO in 2019, Pfizer has been on a buying spree.
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.